Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 5/2016

01-05-2016 | Review

Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease

Authors: Shapur Ikhtaire, Mohammad Sharif Shajib, Walter Reinisch, Waliul Islam Khan

Published in: Journal of Gastroenterology | Issue 5/2016

Login to get access

Abstract

Gastrointestinal symptoms such as abdominal pain, dyspepsia, and diarrhea are relatively nonspecific and a common cause for seeking medical attention. To date, it is challenging for physicians to differentiate between functional and organic gastrointestinal conditions and it involves the use of serological and endoscopic techniques. Therefore, a simple, noninvasive, inexpensive, and effective test would be of utmost importance in clinical practice. Fecal calprotectin (FC) is considered to be a reliable biomarker that fulfills these criteria. FC can detect intestinal inflammation, and its level correlates well with macroscopic and histological inflammation as detected by colonoscopy and biopsies, respectively. FC has a decent diagnostic accuracy for differentiating organic diseases and functional disorders because of its excellent negative predictive value in ruling out inflammatory bowel disease (IBD) in symptomatic undiagnosed patients. There is accumulating evidence that FC has been effectively used to monitor the natural course of IBD, to predict relapse, and to see the response to treatment. This novel biomarker has the ability to assess mucosal healing (MH), which is a therapeutic goal in IBD management. A literature search was carried out using PubMed with the keywords FC, IBD, intestinal inflammation, and MH. In our review, we provide an overview of the utility and scope of FC as a biomarker in patients with IBD as well as undiagnosed patients with lower gastrointestinal symptoms.
Literature
1.
Cho JH, Brant SR. Recent insights into the genetics of inflammatory bowel disease. Gastroenterology. 2011;140(6):1704–12e1702.
2.
Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1720–28e1723.
3.
Abraham C, Medzhitov R. Interactions between the host innate immune system and microbes in inflammatory bowel disease. Gastroenterology. 2011;140(6):1729–37.PubMedPubMedCentralCrossRef
4.
Kaser A, Blumberg RS. Autophagy, microbial sensing, endoplasmic reticulum stress, and epithelial function in inflammatory bowel disease. Gastroenterology. 2011;140(6):1738–47e1732.
5.
6.
Gismera CS, Aladren BS. Inflammatory bowel diseases: a disease (s) of modern times? Is incidence still increasing? World J Gastroenterol. 2008;14(36):5491–8.PubMedPubMedCentralCrossRef
7.
Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58(11):1490–7.PubMedCrossRef
8.
9.
Nielsen OH, Vainer B, Madsen SM, et al. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359–67.PubMed
10.
Bjerke K, Halstensen TS, Jahnsen F, et al. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut. 1993;34:1357–63.PubMedPubMedCentralCrossRef
11.
12.
Fagerhol MK, Dale I, Anderson I. Release and quantification of leukocyte derived protein (L1). Scand J Haematol. 1980;24:393–8.CrossRef
13.
Frosch M, Metze D, Foell D, et al. Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol. 2005;14:259–65.PubMedCrossRef
14.
Foell D, Frosch M, Sorg C, et al. Phagocyte-specific calcium binding S100 proteins as clinical laboratory markers of inflammation. Clin Chim Acta. 2004;344:37–51.PubMedCrossRef
15.
Poullis A, Foster R, Northfield TC, et al. Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002;16:675–81.PubMedCrossRef
16.
Taghvaei T, Maleki I, Nagshvar F, et al. FC and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis. Intern Emerg Med. 2015;10:321–8.PubMedCrossRef
17.
Judd TA, Day AS, Lemberg DA, et al. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol. 2011;26:1493–9.PubMedCrossRef
18.
Voganatsi A, Panyutich A, Miyasaki KT, et al. Mechanism of extracellular release of human neutrophil calprotectin complex. J Leukoc Biol. 2001;70:130–4.PubMed
19.
Rammes A, Roth J, Goebeler M, et al. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997;272:9496–502.PubMedCrossRef
20.
Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:661–5.PubMedCrossRef
21.
Vermeire S, Van Assche G, Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol. 2005;2:580–6.PubMedCrossRef
22.
Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50–4.PubMedCrossRef
23.
24.
Gaya DR, Lyon TD, Duncan A, et al. Faecal calprotectin in the assessment of Crohn’s disease activity. Q J Med. 2005;98:435–41.CrossRef
25.
Reinisch W, Panes J, Page K, et al. Discrepancy between fecal biomarkers and their intestinal gene expression in ulcerative colitis: results from an anti-il-13 antibody study. Gastroenterology. 2014;146(5):S-586.
26.
Bjarnason I, Sherwood R. FC: a significant step in the noninvasive assessment of intestinal inflammation. J Pediatr Gastrenterol Nutr. 2001;33:11–3.CrossRef
27.
Bunn SK, Bisset WM, Main MJ, et al. FC: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastrenterol Nutr. 2001;33:14–22.CrossRef
28.
Summerton CB, Longlands MG, Wiener K, et al. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14:841–5.PubMedCrossRef
29.
Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793–8.PubMedCrossRef
30.
Fagerberg UL, Loof L, Merzoug RD, et al. FC levels in healthy children studied with an improved assay. J Pediatr Gastrenterol Nutr. 2003;37:468–72.CrossRef
31.
Abildtrup M, Kingsley GH, Scott DL. Calprotectin as a biomarker for rheumatoid arthritis: a systematic review. J Rheumatol. 2015;42:760–70.PubMedCrossRef
32.
Meuwis MA, Vernier-Massouille G, Grimaud JC, et al. Serum calprotectin as a biomarker for Crohn’s disease. J Crohns Colitis. 2013;7:e678–83.PubMedCrossRef
33.
Dhaliwal A, Zeino Z, Tomkins C, et al. Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply? Frontline Gastroenterol. 2015;6(1):14–9.PubMedPubMedCentralCrossRef
34.
Lasson A, Stotzer PO, Ohman L, et al. The intraindividual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9(1):26–32.PubMed
35.
36.
Labaere D, Smismans A, Olmen AV, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United Eur Gastroenterol J. 2014;2(1):30–7.CrossRef
37.
Inoue K, Aomatsu T, Yoden A, et al. Usefulness of a novel and rapid assay system for FC in pediatric patients with inflammatory bowel diseases. J Gastroenterol Hepatol. 2014;29:1406–12.PubMedCrossRef
38.
Angriman I, Scarpa M, D’Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63–8.PubMedCrossRef
39.
Shastri Y, Povse N, Stein J. Prospective comparative study for new rapid bedside FC test with an established ELISA to assess intestinal inflammation. Clin Lab. 2009;55:53–5.PubMed
40.
Coorevits L, Baert FJ, Vanpoucke HJ. Faecal calprotectin: comparative study of the Quantum Blue rapid test and an established ELISA method. Clin Chem Lab Med. 2013;51(4):825–31.PubMedCrossRef
41.
Verstergaard TA, Nielsen SL, Dahlerup JF, et al. FC: assessment of a rapid test. Scand J Clin Lab Invest. 2008;68:343–7.CrossRef
42.
Otten CM, Kok L, Witteman BJ, et al. Diagnostic performance of rapid tests for detection of FC and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome. Clin Chem Lab Med. 2008;46:1275–80.PubMedCrossRef
43.
Damms A, Bischoff SC. Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases. Int J Colorectal Dis. 2008;23:985–92.PubMedCrossRef
44.
Lobatón T, Rodríguez-Moranta F, Lopez A, et al. A new rapid quantitative test for FC predicts endoscopic activity in ulcerative colitis. Inflamm Bowel Dis. 2013;19(5):1034–42.PubMedCrossRef
45.
Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Ther Adv Gastroenterol. 2015;8(1):23–36.CrossRef
46.
47.
Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis. 2009;41:56–66.PubMedCrossRef
48.
Kapel N, Campeotto F, Kalach N, et al. Faecal calprotectin in term and preterm neonates. J Pediatr Gastrenterol Nutr. 2010;51(5):542–7.CrossRef
49.
Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of FC for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803–13.CrossRef
50.
Mosli MH, Zou G, Garg SK, et al. C-reactive protein, FC, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802–19.PubMedCrossRef
51.
Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: FC for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–15.PubMedCrossRef
52.
Nancey S, Boschetti G, Moussata D, et al. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases. Inflamm Bowel Dis. 2013;19:1043–52.PubMedCrossRef
53.
Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.PubMedCrossRef
54.
Husebye E, Ton H, Johne B. Biological variability of FC in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96:2683–7.PubMed
55.
Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by FC: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomark Prev. 2004;13:279–84.CrossRef
56.
Dobrzanski C, Pedersen N, Hansen VV, et al. P483. Faecal calprotectin exhibits diurnal variation in inflammatory bowel disease patients but is not affected by time of day. J Crohns Colitis. 2014;S268.
57.
Gibbs J, Ince L, Matthews L, et al. An epithelial circadian clock controls pulmonary inflammation and glucocorticoid action. Nat Med. 2014;20(8):919–26.PubMedPubMedCentralCrossRef
58.
Foster R, Bjarnason I, Roseth AG, et al. Alcohol misuse causes a reversible inflammatory enteropathy with increased intestinal permeability. Alcohol. 1995;30:C5.2.
59.
60.
Poullis A, Foster R, Mendall MA. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. Eur J Gastroenterol Hepatol. 2003;15:573–4.PubMedCrossRef
61.
Meucci G, D’Inca R, Maieron R, et al. Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: a multicenter prospective study. Dig Liver Dis. 2010;42(3):191–5.PubMedCrossRef
62.
Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology. 2002;123(2):450–60.PubMedCrossRef
63.
Roseth AG. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis. 2003;35:607–9.PubMedCrossRef
64.
Konikoff MR, Denson LA. Role of FC as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524–34.PubMedCrossRef
65.
Van Rheenen P, Van de Vijver E, Fiddler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.PubMedPubMedCentralCrossRef
66.
Chang MH, Chou JW, Chen SM, et al. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome. Mol Med Rep. 2014;10(1):522–6.PubMed
67.
Henderson P, Anderson N, Wilson D. The diagnostic accuracy of FC during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:637–45.PubMedCrossRef
68.
69.
Langhorst J, Elsenbruch S, Koelzer J, et al. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1):162–9.PubMedCrossRef
70.
Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70(3):439–44.PubMed
71.
72.
Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13(9):1100–5.PubMedCrossRef
73.
Xiang JY, Ouyang Q, Li GD, et al. Clinical value of FC in determining disease activity of ulcerative colitis. World J Gastroenterol. 2008;14(1):53–7.PubMedPubMedCentralCrossRef
74.
Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2008;6(11):1218–24.PubMedCrossRef
75.
Schoepfer AM, Beglinger C, Straumann A, et al. FC correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol. 2010;105(1):162–9.PubMedCrossRef
76.
Ricanek P, Brackmann S, Perminow G, et al.; IBSEN II Study Group. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical and fecal biomarkers. Scand J Gastroenterol. 2011;46(9):1081–91.
77.
Stange EF, Travis SP, Vermeire S, et al.; European Crohn’s and Colitis Organisation (ECCO). European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis. 2008;2(1):1–23.
78.
Van Assche G, Dignass A, Panes J, et al.; European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: definitions and diagnosis. J Crohns Colitis. 2010;4(1):7–27.
79.
Bunn SK, Bisset W, Main M, et al. FC as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastrenterol Nutr. 2001;32:171–7.CrossRef
80.
Canani R, Terrin G, Rapacciuolo L, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis. 2008;40:547–53.PubMedCrossRef
81.
Fagerberg U, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by FC in children with gastrointestinal symptoms. J Pediatr Gastrenterol Nutr. 2005;40:450–5.CrossRef
82.
Limburg PJ, Ahlquist DA, Sandborn WJ, et al. FC levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol. 2000;95:2831–7.PubMedCrossRef
83.
Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis. 2003;35:642–7.PubMedCrossRef
84.
D’Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429–37.PubMedCrossRef
85.
Sipponen T, Kolho KL. Faecal calprotectin in children with clinically quiescent inflammatory bowel disease. Scand J Gastroenterol. 2010;45(7–8):872–7.PubMedCrossRef
86.
Tibble JA, Bjarnason I. FC as an index of intestinal inflammation. Drugs Today (Barc). 2001;37:85–96.CrossRef
87.
88.
Mao R, Xiao Y, Gao X, et al. FC in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2012;18:1894–9.PubMedCrossRef
89.
Walkiewicz D, Werlin S, Fish D, et al. FC is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008;14:669–73.PubMedCrossRef
90.
Mooiweer E, Severs M, Schipper ME, et al. Low FC predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015;9(1):50–5.PubMedCrossRef
91.
Louis E, Mary J, Vernier-Massouille G, et al. Groupe D’etudes Thérapeutiques Des Affections Inflammatoires Digestives. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.PubMedCrossRef
92.
Gisbert JP, Bermejo F, Perez-Calle JL, et al. FC and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15:1190–8.PubMedCrossRef
93.
Molander P, Färkkilä M, Ristimäki A, et al. Does FC predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015;9(1):33–40.PubMed
94.
Ferreiro-Iglesias R, Barreiro-de Acosta M, Otero Santiago M, et al. FC as predictor of relapse in patients with inflammatory bowel disease under maintenance infliximab therapy. J Clin Gastroenterol. 2016;50(2):147–51.PubMedCrossRef
95.
Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005;54(3):364–8.PubMedPubMedCentralCrossRef
96.
D’Inca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease? Am J Gastroenterol. 2008;103:2007–14.PubMedCrossRef
97.
Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does FC predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4:144–52.PubMedCrossRef
98.
De Vos M, Louis EJ, Jahnsen J, et al. Consecutive FC measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013;19:2111–7.PubMedCrossRef
99.
Roseth AG, Aadland E, Grzyb K. Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol. 2004;39:1017–20.PubMedCrossRef
100.
Molander P, Af Bjorkesten C, Mustonen H, et al. FC concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents. Inflamm Bowel Dis. 2012;18:2011–7.PubMedCrossRef
101.
Wagner M, Peterson CG, Ridefelt P, et al. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14(36):5584–9.PubMedPubMedCentralCrossRef
102.
Sipponen T, Savilahti E, Karkkainen P, et al. FC, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis. 2008;14(10):1392–8.PubMedCrossRef
103.
Ho GT, Lee HM, Brydon G, et al. FC predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol. 2009;104(3):673–8.PubMedCrossRef
104.
Kolho KL, Raivio T, Lindahl H, et al. FC remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720–5.PubMedCrossRef
105.
Kolho K, Sipponen T. The long-term outcome of anti-tumor necrosis factor-α therapy related to FC values during induction therapy in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2014;49:434–41.PubMedCrossRef
106.
Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15–29.PubMedCrossRef
107.
Mazzuolia S, Guglielmi FW, Antonellib E, et al. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969–77.CrossRef
108.
Peyrin-Biroulet L, Ferrante M, Magro F, et al.; Scientific Committee of the European Crohn’s and Colitis Organization. Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease. J Crohns Colitis. 2011;5:477–483.
109.
D’Haens G, Ferrante M, Vermeire S, et al. FC is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2218–24.PubMedCrossRef
110.
Williams JG, Wong WD, Rothenberger DA, et al. Recurrence of Crohn’s disease after resection. Br J Surg. 1991;78:10–9.PubMedCrossRef
111.
Boschetti G, Laidet M, Moussata D, et al. Levels of FC are associated with the severity of postoperative endoscopic recurrence in asymptomatic patients with Crohn’s disease. Am J Gastroenterol. 2015;110:865–72.PubMedCrossRef
112.
Orlando A, Modesto I, Castiglione F, et al. The role of calprotectin in predicting endoscopic post-surgical recurrence in asymptomatic Crohn’s disease: a comparison with ultrasound. Eur Rev Med Pharmacol Sci. 2006;10:17–22.PubMed
113.
Scarpa M, D’Inca R, Basso D, et al. Fecal lactoferrin and calprotectin after ileocolonic resection for Crohn’s disease. Dis Colon Rectum. 2007;50:861–9.PubMedCrossRef
114.
Papay P, Ignjatovic A, Karmiris K, et al. Optimising monitoring in the management of Crohn’s disease: a physician’s perspective. J Crohns Colitis. 2013;7:653–69.PubMedCrossRef
115.
Shen B, Fazio VW, Remzi FH, et al. Clinical approach to diseases of ileal pouch-anal anastomosis. Am J Gastroenterol. 2005;100:2796–807.PubMedCrossRef
116.
Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology. 1994;107:1856–60.PubMed
117.
Lohmuller JL, Pemberton JH, Dozois RR, et al. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Ann Surg. 1990;211:622–7.PubMedPubMedCentral
118.
Stavlo PL, Libsch KD, Rodeberg DA, et al. Pediatric ileal pouch-anal anastomosis: functional outcomes and quality of life. J Pediatr Surg. 2003;38:935–9.PubMedCrossRef
119.
Shepherd NA, Jass JR, Duval I, et al. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. J Clin Pathol. 1987;40:601–7.PubMedPubMedCentralCrossRef
120.
Thomas P, Rihani H, Roseth A, et al. Assessment of ileal pouch inflammation by single-stool calprotectin assay. Dis Colon Rectum. 2000;43:214–20.PubMedCrossRef
121.
Johnson MW, Maestranzi S, Duffy AM, et al. FC: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur J Gastroenterol Hepatol. 2008;20:174–9.PubMedCrossRef
122.
Yamamoto T, Shimoyama T, Bamba T, et al. Consecutive monitoring of FC and lactoferrin for the early diagnosis and prediction of pouchitis after restorative proctocolectomy for ulcerative colitis. Am J Gastroenterol. 2015;110:881–7.PubMedCrossRef
123.
Pakarinen MP, Koivusalo A, Natunen J, et al. FC mirrors inflammation of the distal ileum and bowel function after restorative proctocolectomy for pediatric onset ulcerative colitis. Inflamm Bowel Dis. 2010;16(3):482–6.PubMedCrossRef
124.
Lehmann F, Trapani F, Fueglistaler I, et al. Clinical and histopathological correlations of FC release in colorectal carcinoma. World J Gastroenterol. 2014;20:4994–9.PubMedPubMedCentralCrossRef
125.
Moum B, Jahnsen J, Bernklev T. FC variability in Crohn’s disease. Inflamm Bowel Dis. 2010;16:1091–2.PubMedCrossRef
126.
Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin N Am. 2012;41(2):483–95.CrossRef
127.
Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110(3):444–54.PubMedCrossRef
128.
Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut. 2007;56:1706–13.PubMedPubMedCentralCrossRef
129.
Sidler M, Leach S, Day A. Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2008;14:359–66.PubMedCrossRef
130.
Nakarai A, Kato J, Sakiko Hiraoka S, et al. Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test. Am J Gastroenterol. 2013;108:83–9.PubMedCrossRef
131.
Mooiweer E, Fidder HH, Siersema PD, et al. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation. Inflamm Bowel Dis. 2014;20:307–14.PubMedCrossRef
132.
Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873–80.PubMedCrossRef
133.
Kennedy NA, Clark A, Walkden A, et al. Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16–50 years. J Crohns Colitis. 2015;9(1):41–9.PubMedPubMedCentral
134.
Froehlich F, Gonvers JJ. Diagnostic yield of colonoscopy by indication. In: Wayne JD, Rex DK, Williams CB, editors. Colonoscopy: principles and practice. Massachusetts: Wiley-Blackwell; 2003. p. 111.CrossRef
Metadata
Title
Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease
Authors
Shapur Ikhtaire
Mohammad Sharif Shajib
Walter Reinisch
Waliul Islam Khan
Publication date
01-05-2016
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 5/2016
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1182-4

Other articles of this Issue 5/2016

Journal of Gastroenterology 5/2016 Go to the issue

Letter to the Editor

Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

Review

Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience

Original Article—Alimentary Tract

Esophageal motility after peroral endoscopic myotomy for achalasia

Letter to the Editor

Reply to the letter by Takeshi Yamada et al. concerning “Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?”

Original Article—Liver, Pancreas, and Biliary Tract

Appropriate use of virtual touch quantification and FibroScan® M and XL probes according to the skin capsular distance

Original Article—Liver, Pancreas, and Biliary Tract

Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits